{
    "clinical_study": {
        "@rank": "106056", 
        "arm_group": [
            {
                "arm_group_label": "700 \u03bcg dexamethasone", 
                "arm_group_type": "Experimental", 
                "description": "700 \u03bcg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10."
            }, 
            {
                "arm_group_label": "Laser Photocoagulation", 
                "arm_group_type": "Other", 
                "description": "Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of 700 \u03bcg dexamethasone versus laser\n      photocoagulation in patients with diabetic macular edema (DME)."
        }, 
        "brief_title": "A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of diabetes mellitus (type 1 or type 2)\n\n          -  Presence of macular edema\n\n        Exclusion Criteria:\n\n          -  Anticipated need for ocular surgery in the study eye during the study\n\n          -  Laser photocoagulation in the study eye within 3 months\n\n          -  Cataract surgery within 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "356", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121262", 
            "org_study_id": "206207-026"
        }, 
        "intervention": [
            {
                "arm_group_label": "700 \u03bcg dexamethasone", 
                "description": "700 \u03bcg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10.", 
                "intervention_name": "700 \u03bcg dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "OZURDEX\u00ae"
            }, 
            {
                "arm_group_label": "Laser Photocoagulation", 
                "description": "Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated.", 
                "intervention_name": "Laser Photocoagulation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Makati City", 
                        "country": "Philippines"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Korea, Republic of", 
                "Philippines", 
                "Singapore"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Patients with BCVA Improvement \u226515 Letters from Baseline in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }, 
            {
                "measure": "Change from Baseline in Central Retinal Thickness by Optical Coherence Tomography (OCT) in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }, 
            {
                "measure": "Change from Baseline in Total Macular Leakage Area by Fluorescein Angiography (FA) in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}